Research Study

An Open-label, Multi-center, Phase 1b Study to Investigate the Safety and Tolerability of SLC-0111 (WBI-5111) in Combination With Gemcitabine in Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) Subjects Positive for Carbonic Anhydrase IX (CAIX)
Principal Investigator 
Daniel Renouf

Overview

Body Locations and Systems 
Pancreatic Cancer
Disorders and Conditions 
Pancreatic Cancer
ClinicalTrials.gov# 
NCT03450018
Status 
Recruiting
Study Start/End 
Aug 1, 2018 to Aug 31, 2020
Locations 
Vancouver General Hospital
Purpose of Study 

The purpose of this study is to identify the safety, tolerability and maximum-tolerated-dose of the oral formulation of SLC-0111 in combination with IV gemcitabine in those with metastatic pancreatic ductal cancer.

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.